These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17490557)

  • 41. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
    Marin D; Goldman JM; Olavarria E; Apperley JF
    Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
    [No Abstract]   [Full Text] [Related]  

  • 46. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 47. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
    Sweet K; Oehler V
    Hematology Am Soc Hematol Educ Program; 2013; 2013():184-8. PubMed ID: 24319180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
    Druker B
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):9-14. PubMed ID: 11526596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.
    Alonci A; Allegra A; Russo S; Penna G; Bellomo G; D'Angelo A; Campo S; Cannavò A; Centorrino R; Musolino C
    Acta Haematol; 2012; 127(1):1-6. PubMed ID: 21986252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New strategies in chronic myeloid leukemia.
    Kantarjian HM; Cortes J
    Int J Hematol; 2006 May; 83(4):289-93. PubMed ID: 16757426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
    Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
    [No Abstract]   [Full Text] [Related]  

  • 52. Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
    Sakamoto E; Sawada T; Osugi H; Nakamae H; Koh KR; Yamane T; Ohsawa M; Wakasa K; Hino M
    Int J Hematol; 2008 Oct; 88(3):348-350. PubMed ID: 18758897
    [No Abstract]   [Full Text] [Related]  

  • 53. Selective effect of imatinib on serum IgM in a patient with CML.
    Nagasawa M; Mizutani S
    Int J Hematol; 2004 Nov; 80(4):381-2. PubMed ID: 15615266
    [No Abstract]   [Full Text] [Related]  

  • 54. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.
    Elias MH; Baba AA; Husin A; Sulong S; Hassan R; Sim GA; Abdul Wahid SF; Ankathil R
    Biomed Res Int; 2013; 2013():129715. PubMed ID: 23484077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic drug monitoring in CML patients on imatinib.
    Blasdel C; Egorin MJ; Lagattuta TF; Druker BJ; Deininger MW
    Blood; 2007 Sep; 110(5):1699-701; author reply 1701. PubMed ID: 17712052
    [No Abstract]   [Full Text] [Related]  

  • 57. What does a deep molecular response signify?
    Politi J; Shah NP
    J Clin Oncol; 2014 Feb; 32(5):471-4. PubMed ID: 24297955
    [No Abstract]   [Full Text] [Related]  

  • 58. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Horn M; Glauche I; Müller MC; Hehlmann R; Hochhaus A; Loeffler M; Roeder I
    Blood; 2013 Jan; 121(2):378-84. PubMed ID: 23175686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reply to J. Richter et al.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Sep; 32(25):2823-5. PubMed ID: 25071119
    [No Abstract]   [Full Text] [Related]  

  • 60. [Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
    Katagiri S; Tauchi T; Umezu T; Saito Y; Suguro T; Asano M; Yoshizawa S; Kitahara T; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Ito Y; Ohyashiki JH; Ohyashiki K
    Rinsho Ketsueki; 2015 Feb; 56(2):216-9. PubMed ID: 25765803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.